|
1
|
National Cancer Institute (NCI), . Cancer stat facts: Ovarian cancer. https://seer.cancer.gov/statfacts/html/ovary.htmlDecember 20–2024
|
|
2
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, et al: Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 397:2182–2193. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, et al: Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol. 35:1411–1420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forstner R: Early detection of ovarian cancer. Eur Radiol. 30:5370–5373. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, Millet I, Bharwani N, Juhan V, Cunha TM, et al: Ovarian-Adnexal reporting data system magnetic resonance imaging (O-RADS MRI) score for risk stratification of sonographically indeterminate adnexal masses. JAMA Netw Open. 3:e19198962020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engbersen MP, Van Driel W, Lambregts D and Lahaye M: The role of CT, PET-CT, and MRI in ovarian cancer. Br J Radiol. 94:202101172021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ and Shih IM: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al: Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 106:dju2492014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann Oncol. 31:1491–1505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al: ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2:ijgc-2019-000308. 2019.
|
|
16
|
Hirasawa T, Yasuda M, Muramatsu T, Itoh H, Shinozuka T, Makino T, Tsutsumi Y and Osamura RY: Cytologic study of ascites and the endometrium in ovarian carcinoma. Clinical significance. Acta Cytol. 41:1451–1455. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, et al: Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 10:eaap87932018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akahane T, Yamaguchi T, Kato Y, Yokoyama S, Hamada T, Nishida Y, Higashi M, Nishihara H, Suzuki S, Ueno S and Tanimoto A: Comprehensive validation of liquid-based cytology specimens for next-generation sequencing in cancer genome analysis. PLoS One. 14:e02177242019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ab Mutalib NS, Syafruddin SE, Zain RR, Dali AZ, Yunos RI, Saidin S, Jamal R and Mokhtar NM: Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach. BMC Res Notes. 7:8052014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, Tanaka D, Isogai T, Imai JI, Watanabe S and Fujimori K: Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy. Sci Rep. 10:187342020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watanabe T, Nanamiya H, Endo Y, Kojima M, Nomura S, Furukawa S, Soeda S, Tamura H, Ryufuku M, Tanaka D, et al: Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. J Ovarian Res. 14:1292021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schneider G, Schmidt-Supprian M, Rad R and Saur D: Tissue-specific tumorigenesis: Context matters. Nat Rev Cancer. 17:239–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nimura R, Kondo E, Yoshida K, Kubo-Kaneda M, Nii M, Ikeijiri M, Nakamura M, Imai H, Okugawa Y, Nakatani K and Ikeda T: Cancer-associated gene analysis of cervical cytology samples and liquid-based cytology significantly improve endometrial cancer diagnosis sensitivity. Oncol Lett. 24:3762022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsuura M, Yamaguchi K, Tamate M, Satohisa S, Teramoto M, Iwasaki M, Sugita S, Hasegawa T, Koubo R, Takane K, et al: Efficacy of liquid-based genetic diagnosis of endometrial cancer. Cancer Sci. 109:4025–4032. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akahane T, Kitazono I, Kobayashi Y, Nishida-Kirita Y, Yamaguchi T, Yanazume S, Tabata K, Kobayashi H and Tanimoto A: Direct next-generation sequencing analysis using endometrial liquid-based cytology specimens for rapid cancer genomic profiling. Diagn Cytopathol. 49:1078–1085. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H and Aoki D: Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget. 8:112258–112267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Žilovič D, Vaicekauskaitė I, Čiurlienė R, Sabaliauskaitė R and Jarmalaitė S: Uterine cavity lavage mutation analysis in lithuanian ovarian cancer patients. Cancers (Basel). 15:8682023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
SEER*Explorer, . An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2024, https://seer.cancer.gov/statistics-network/explorer/application.html?site=61&data_type=1&graph_type=2&compareBy=race&chk_race_6=6&chk_race_5=5&chk_race_4=4&chk_race_9=9&chk_race_8=8&rate_type=2&hdn_sex=3&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0December 20–2024
|
|
29
|
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, et al: Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 9:43192018. View Article : Google Scholar : PubMed/NCBI
|
